We have generated F9 murine embryonal carcinoma cells in which either the retinoid X receptor (RXR) ␣ and retinoic acid receptor (RAR) ␣ genes or the RXR ␣ and RAR ␥ genes are knocked out, and compared their phenotypes with those of wild-type (WT),
1. Abbreviations used in this paper : AFP, ␣ -fetoprotein; E 2 , estradiol; EC, embryonal carcinoma; EMSA, electrophoretic mobility shift assays; HR, homologous recombination; PGK, phosphoglycerate kinase; RAR, retinoic acid receptor; RXR, retinoid X receptor; RARE, retinoic acid response element; RT, reverse transcription; tRA, all-trans retinoic acid; VE, visceral endoderm; WT, wild-type.
R
etinoids exert their pleiotropic effects on vertebrate development, cellular differentiation, proliferation, and homeostasis through two classes of ligand-dependent transactivators: the retinoic acid receptors (RARs) 1 , and the retinoid X receptors (RXRs) (for reviews see De Luca, 1991; Blomhoff, 1994; Chambon, 1994 Chambon, , 1996 Kastner et al., 1995; Mangelsdorf and Evans, 1995) . RARs are activated by all-trans retinoic acid (tRA) and by 9-cis retinoic acid (9C-RA), whereas RXRs are activated by 9C-RA only. The various RAR (RAR ␣ , ␤ , and ␥ ) and RXR (RXR ␣ , ␤ , and ␥ ) isotypes are encoded by different genes, and their isoforms, which differ in their NH 2 -terminal regions, are generated by differential promoter usage and alternative splicing. The multiple RAR and RXR isotypes and isoforms are conserved in vertebrate evolution, and display distinct spatiotemporal expression patterns in developing embryos and adult tissues, suggesting that each receptor performs some unique functions (for reviews see Leid et al., 1992 a ; Chambon, 1994; Kastner et al., 1994) . RXR/RAR heterodimers bind much more efficiently to retinoic acid response elements (RAREs) than their respective homodimers in vitro (for reviews see Leid et al., 1992 a ; Chambon, 1994 Chambon, , 1996 Giguère, 1994; Glass, 1994; Kastner et al., 1994; Mangelsdorf et al., 1994; Gronemeyer and Laudet, 1995; Keaveney and Stunnenberg, 1995; Mangelsdorf and Evans, 1995) , and several lines of evidence support the idea that these heterodimers represent the functional units transducing the retinoid signal in vivo (Kastner et al., 1995; Chambon, 1996) .
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The F9 murine embryonal carcinoma (EC) cell line expresses all types of RARs and RXRs (Zelent et al., 1989; Martin et al., 1990; Wan et al., 1994) , and upon retinoic acid treatment, it differentiates into cells resembling three distinct extraembryonic endoderm (primitive, parietal, and visceral) , depending on the culture conditions (for reviews see Strickland, 1981; Hogan et al., 1983; Gudas et al., 1994) . Retinoid-induced differentiation is accompanied by an apoptotic response and a dramatic decrease in the rate of proliferation (Sleigh, 1992; Atencia et al., 1994; Clifford et al., 1996) . Thus, F9 cells provide an attractive system for the analysis of retinoid signaling in vivo.
To further investigate the roles of RXRs and RARs in differentiation, proliferation, and apoptosis, we have now generated F9 cells lacking either RXR ␣ and RAR ␣ , or RXR ␣ and RAR ␥ , and then compared their phenotypes with those of wild-type (WT), RXR ␣ Ϫ / Ϫ , RAR ␣ Ϫ / Ϫ , and RAR ␥ Ϫ / Ϫ (Boylan et al., 1993; Taneja et al., 1995) F9 cells. Multiple gene targeting in a given cell has been achieved by using a Cre/ loxP system (Sauer and Henderson, 1990; Metzger et al., 1995) , which allows removal of the antibiotic resistance gene from a targeted locus, and therefore subsequent mutagenesis of the second allele of a given gene with the same targeting construct, as well as the targeting of additional genes. We demonstrate that tRA-treated RXR ␣ Ϫ / Ϫ / RAR ␣ Ϫ / Ϫ cells differentiate poorly into primitive and parietal endodermlike cells and are impaired in both antiproliferative and apoptotic responses, whereas they fully differentiate into visceral endoderm (VE)-like cells, as previously observed for RXR ␣ Ϫ / Ϫ cells . In contrast, RXR ␣ Ϫ / Ϫ /RAR ␥ Ϫ / Ϫ cells are defective for all three types of endodermal differentiation, as well as for the antiproliferative and apoptotic responses, indicating that the absence of both RXR ␣ and RAR ␥ cannot be functionally compensated by the other retinoid receptors in these cells. Taken together with results obtained by treatment of WT and mutant F9 cells with panRXR-and RAR isotypeselective retinoids, our findings support the conclusion that RXR/RAR heterodimers are the functional units mediating the retinoid signal in vivo. Furthermore our results indicate that RXR/RAR heterodimers can exert both specific and redundant functions in differentiation, proliferation, and apoptosis. We also show that functional redundancy between RXR isotypes and between RAR isotypes can be artifactually generated by gene knockouts.
Materials and Methods

Cell Culture
F9 cells were cultured and induced to differentiate into primitive, parietal, and visceral endodermlike cells as previously described (Boylan et al., 1993; Clifford et al., 1996) . The retinoids (tRA, Am80, BMS753, BMS453, BMS961, and BMS649) were dissolved in ethanol.
Targeting of the RAR ␣ or RAR ␥ Genes in RXR ␣ -null F9 Cells.
The RAR ␣ targeting vector, pRAR ␣ (LNL) , was previously described (Metzger et al., 1995) . The RAR ␥ targeting vector, pRAR ␥ (LPL) , was derived from pD ␥ 6.5A (a gift from D. Lohnes, IGBMC, CNRS/INSERM/ ULP, Illkirch, France), which contains a 6-kb genomic fragment including exons 5 and 8. A unique SmaI site, followed by stop codons in all three reading frames, was introduced into pD ␥ 6.5A at the KpnI site located in exon 8 of RAR ␥ by inserting the oligonucleotides 5 Ј -CCCCGGGTAGG-TAGATAGCGTAC-3 Ј and 5 Ј -GCTATCTACCTACCCGGGGGTAC-3 Ј , yielding the pRAR ␥ T4 construct. An XhoI-BamHI fragment containing the phosphoglycerate kinase (PGK) promoter-driven, puromycinresistance (puro) gene, flanked by loxP sites, was isolated from pHRLpuro1, and blunt ended with T4 DNA polymerase, followed by ligation into the SmaI site of pRAR ␥ T4. pHRLpuro1 was constructed from VS-1, a plasmid containing a loxP site-flanked PGKpuroA ϩ cassette, by mutating the SalI site. The PGKpuroA ϩ cassette was obtained by ligating the PGK pro- targeting construct, the WT RAR␣ locus, and the recombined locus after integration (HR[I]) and after Cre-mediated excision (HR[E] ). Dark boxes indicate exons. The exons 4-8 encoding the NH 2 -terminal part of minor isoforms (RAR␣3-7) (Leroy et al., 1991) are not represented. Restriction enzyme sites and the location of probes are indicated. The neo and a1 probes have been previously described (Metzger et al., 1995 LNL) cell lines. Lanes 1 and 2 contain 2 g of whole cell extracts from COS cells transfected with either the pSG5 (Green et al., 1988) or mRAR␣ø expression construct (Zelent et al., 1989) , and lanes 3-6 contain 60 g of whole cell extracts from WT and mutant F9 cells, as indicated. RAR␣ protein was detected using the rabbit polyclonal antibody RP␣(F), followed by chemiluminescence detection. Mol wt is shown in kD. targeting construct, the WT RAR␥ locus, and the recombined locus after integration (HR [I] ) and after Cre-mediated excision (HR[E] ). Dark boxes indicate exons. The exons 6 and 7 encoding the NH 2 -terminal part of minor isoforms (RAR␥4 and 6; Kastner et al., 1990) are not represented. Restriction enzyme sites and the location of probes are indicated. The puro probe corresponds to a 0.7-kb EcoRI-XbaI fragment derived from pHRLpuro1. The r1 probe corresponds to a 1.5-kb BamHI-EcoRI fragment derived from the RAR␥ genomic clone G1mRAR␥ . The r2 probe corresponds to a 1.6-kb EcoRI-PstI fragment derived from pRAR␥ (LPL) 
A radiolabeled oligonucleotide corresponding to the Hoxa-1/RAR␤ RARE was incubated with 20 g of whole cell extracts from WT cells (lanes 1 and 4) , LNL) cells (lanes 2 and 5) and RAR␥ Ϫ/Ϫ cells (lanes 3 and 6), or with 2 g of whole cell extracts from COS cells transfected with either the pSG5 (lanes 7 and 9; Green et al., 1988) or mRAR␥ø expression construct (lanes 8 and 10; Zelent et al., 1989) , together with 0.5 g of whole cell extracts from COS cells transfected with mRXR␣ø expression construct (Leid et al., 1992b) . The arrows indicate the shifted complex formed in the presence of mouse monoclonal antibodies Ab2␥(F) and Ab10␥ (A2).
moter (a 500-bp EcoRI-PstI fragment isolated from pKJ-1 [Adra et al., 1987] ) to the coding sequence of the puro gene (a 600-bp HindIII-ClaI fragment isolated from pLXPB [Imler et al., 1996] ), and by inserting the SV-40 polyadenylation signal (a 160-bp BglII-XbaI fragment isolated from pSG5 [Green et al., 1988] ) using synthetic oligonucleotides. This cloning resulted in the loss of the PstI, HindIII, and ClaI restriction sites, and the introduction of HindIII and EcoRI sites at 5Ј and 3Ј ends of the PGK promoter, respectively. KpnI, ApaI, XhoI, and BglII restriction sites, and BamHI and SacI sites are located at 5Ј and 3Ј ends of the loxP-flanked cassette, respectively.
Electroporation, selection of neomycin-resistant clones, Cre-mediated excision of the resistance genes, and Southern blot analysis were performed as previously described (Metzger et al., 1995; Clifford et al., 1996) . Puromycin selection (500 ng/ml) was carried out for 10 d.
Western Blotting and Electrophoretic Mobility Shift Assays (EMSA)
Isolation of whole cell extracts from F9 cells and transfected COS-1 cells, Western blot analysis, and electrophoretic mobility shift assays were performed as previously described (Rochette-Egly et al., 1991; Gaub et al., 1992; Boylan et al., 1993) .
Reverse Transcription (RT)-PCR
RNA preparation, RT-PCR, and Southern blotting were performed as previously described Roy et al., 1995) . The PCR primers and end-labeled oligonucleotide probes for collagen IV␣1, laminin B1, ␣-fetoprotein (AFP), and 36B4, were described previously . Transcript levels were quantified using a BAS 2000 bioimaging analyzer (Fuji Ltd., Tokyo, Japan), and were normalized to the corresponding 36B4 signals.
Analysis of Cellular Growth
Cells were plated in triplicate 3-cm culture wells (5 ϫ 10 2 cells per well), and cell counting experiments were performed as previously described . [
3 H]Thymidine incorporation assays were performed essentially as described , with the following modifications. Cells were cultured for 4 d in six replicate 3-cm wells, in the presence or absence of 1 M tRA, and three of the six wells were treated with 8 Ci/well [ 3 H]methylthymidine (20.0 Ci/mmol; Dupont-NEN, Boston, MA) for 2 h before harvesting. The cell cycle profile of WT and mutant cells was determined as previously described .
Analysis of Apoptosis
Apoptosis was analyzed by both Hoechst staining of nuclei and FACS ® analysis, as previously described .
Results
Targeted Disruption of the RAR␣ or RAR␥ Genes in RXR␣ Null F9 Cells
The RXR␣-null F9 cell line, C2RXR␣
, which constitutively expresses a ligand-dependent chimeric Crerecombinase (Cre-ER; Metzger et al., 1995) , was electroporated with the targeting constructs pRAR␣ (LNL) (Fig.  1 A) or pRAR␥ (LPL) (Fig. 2 A) to generate F9 cells disrupted in either the RXR␣ and RAR␣ genes or the RXR␣ and RAR␥ genes. These targeting constructs contain translation stop codons and loxP site-flanked neomycinor puromycin-resistance genes in exon 9 of the RAR␣ gene or exon 8 of the RAR␥ gene, respectively (Materials and Methods; Figs. 1 A and 2 A). Since these exons encode the B region, which is common to all isoforms of a given RAR isotype (Kastner et al., 1990; Leroy et al., 1991; Chambon, 1994) , the expression of RAR␣ and RAR␥ proteins is suppressed by these mutations. Homologous recombination (HR) and Cre-mediated excision of the resistance genes were verified by Southern blotting (Figs. 1 B and 2 B).
Southern blot analysis using a 3Ј probe (a1) located outside of the pRAR␣ (LNL) targeting construct ( Fig. 1 A) , indicated that, after electroporation, 5 out of 96 C2RXR␣
neomycin-resistant clones had one targeted RAR␣ allele (Fig. 1, A, HR[I] ; and B, compare lanes 3 and 4 with lanes 1 and 2; data not shown). One RXR␣
cell line (clone nine) was treated with estradiol (E 2 ) to excise the loxP-flanked cassette (Ϫ [LNL] and Ϫ [L] ) designate the targeted allele before and after Cre-mediated excision, respectively). Southern blot analysis using a1 and "neo" probes revealed that excision of the resistance gene occurred in two out of six subclones treated with E 2 (Fig.  1 , A, HR [E] ; and B, compare lane 5 with lanes 3 and 4; see also Metzger et al., 1995) . The second allele of the RAR␣ gene was targeted in the RXR␣ Fig. 1 B, clone 9a) using the same targeting construct and strategy. 2 of 96 neomycin-resistant clones were positive for the desired recombination event, resulting in RXR␣ Fig. 1 B, clones 9a-10 and 9a-26; compare lanes 6 and 7 with lanes 1-5). No wild-type RAR␣ transcripts were detected in RXR␣
) by Western blotting using the polyclonal antibody RP␣(F) (Gaub et al., 1992) , directed against the F region of the RAR␣ protein ( Fig. 1 C, compare lanes 3 and 4 with lanes 2, 5, and 6).
To establish F9 cells in which both RXR␣ and RAR␥ genes are inactivated, C2RXR␣
Ϫ(L)/Ϫ(L) cells were electroporated with the pRAR␥ (LPL) targeting construct (Fig. 2  A) . Southern blot analysis using the r1 probe, located 5Ј to the pRAR␥ (LPL) sequence (Fig. 2 A) , revealed that 3 out of 96 puromycin-resistant clones had one targeted RAR␥ allele (Fig. 2, A, HR[I] ; and B, compare lanes 3 and 4 with lanes 1 and 2; and data not shown). One RXR␣ LPL) cell line (clone 25) was transiently transfected with a Cre recombinase expression construct (pPGK-Cre) , since for unknown reasons the loxPflanked, puromycin-resistance gene was not excised by treatment of the cells with E 2 (data not shown; Ϫ [LPL] and Ϫ[L] designate the targeted allele before and after Cre-mediated excision, respectively). The pattern obtained by Southern blot analysis, using r1, r2, and puro probes, clearly indicated that 2 out of 96 subclones had lost the puromycin-resistance cassette (Fig. 2 The levels of RNA transcripts were expressed relative to the amount present in tRA-treated WT cells, which was taken as 100. The white and black bars correspond to transcript levels expressed in vehicle-and tRA-treated cells, respectively. Bar, 100 m. using the same targeting construct and strategy, yielding a RXR␣ Fig. 2 B, clone  25a-3, compare lane 6 with lanes 1-5) . No wild-type RAR␥ RNA was detected in RXR␣
The absence of RAR␥ protein was verified by EMSA using the monoclonal antibodies Ab2␥(F) and Ab10␥(A2) (Rochette-Egly et al., 1991) , directed against the F and A2 regions of the RAR␥ protein, respectively. No antibody-shifted complex was observed in RXR␣ Fig. 2 C, compare lane 5 with lanes 4, 6, and 10) . Note that the RXR␣ loci, which contain loxP sites, were not rearranged during excision of the resistance genes at the RAR␣ or RAR␥ loci (data not shown). Note also that the knockout of a given receptor(s) did not result in major variations of those remaining (Chiba et al., 1997) .
Function of RXRs and RARs in the Retinoid-induced Differentiation of F9 Cells into Primitive and Parietal Endodermlike Cells
WT F9 cells differentiate into primitive and parietal endodermlike cells, when grown in monolayer culture in the presence of tRA alone and tRA in combination with dibutyryl cAMP (bt 2 cAMP), respectively (Strickland, 1981; Hogan et al., 1983) . Previous studies have shown that these two types of differentiation are severely impaired in RAR␥ Ϫ/Ϫ and RXR␣ Ϫ/Ϫ cells (Boylan et al., 1993; Clifford et al., 1996) . The differentiation patterns of RXR␣ (Fig. 3 A, j-l , and data not shown). This undifferentiated phenotype persisted after 10 d of treatment.
The extent of differentiation of WT and mutant F9 cells was further investigated biochemically by determining the mRNA levels of collagen type IV␣1 and laminin B1, two markers of endodermal differentiation (Fig. 3, B and C) . After 48 h of 1 M tRA treatment, the induction of collagen type IV␣1 and laminin B1 was reduced in RAR␥ Ϫ/Ϫ cells (10-fold and 6-fold lower levels, respectively) and in RXR␣ Ϫ/Ϫ cells (3-fold and 6-fold lower levels, respectively) when compared to WT cells, whereas these inductions were not altered in RAR␣ Ϫ/Ϫ cells (Boylan et al., 1993 Clifford et al., 1996; Taneja et al., 1996) . The induction of both transcripts was also impaired in RXR␣ Ϫ/Ϫ / RAR␣ Ϫ/Ϫ cells (fivefold and sevenfold lower levels, respectively), whereas it was fully abrogated in RXR␣ Ϫ/Ϫ / RAR␥ Ϫ/Ϫ cells. Thus, RA-induced primitive and parietal endodermal differentiation of WT F9 cells appears to be mainly mediated by the RXR␣/RAR␥ pair, whereas it cannot be mediated by combinations of RXR(␤ϩ␥) with either RAR␣ or RAR␤ (see Table IV ).
Function of RXRs and RARs in the Retinoid-induced Differentiation of F9 Cells into VE-like Cells
When F9 cells are grown in suspension as aggregates, low levels of tRA induce a VE phenotype in the outermost layer of cells, which display an irregular surface (Strickland, 1981; Hogan et al., 1983 ; see also Fig. 4 A, WT, a and  b, brackets) . We have previously shown that, in contrast to primitive and parietal endodermal differentiation, VE differentiation can be induced by tRA in RXR␣ Ϫ/Ϫ F9 cells . Similarly, after 10 d of treatment, (Fig. 4 A, compare f with panels b and d; and Table I ). In contrast, Ͻ10% of the outer layer of RAR␥ Ϫ/Ϫ cells exhibited VE conversion after 10 d of treatment, whereas full VE differentiation was eventually achieved after 14 d of treatment (Fig. 4 A, compare h with g and b; and Table I ). In RXR␣
Ϫ/Ϫ
/RAR␥
Ϫ/Ϫ cells, the surface of the aggregates was as smooth after 10 d of treatment as in untreated controls (Fig. 4 A, compare j with a and i), and Ͻ10% of the aggregates displayed only a spotty VE conversion after 12 or 18 d of treatment (Table I) . To exclude the possibility that this very poor differentiation of the RXR␣
Ϫ/Ϫ
/RAR␥
Ϫ/Ϫ cells could be due to some clonal variation, rather than the presence of the RXR␣-null mutation in the RAR␥-null background, we expressed the RXR␣ cDNA in RXR␣ Ϫ/Ϫ /RAR␥ Ϫ/Ϫ cells. As expected, cells expressing the RXR␣ cDNA exhibited a phenotype identical to that of RAR␥ Ϫ/Ϫ cells, i.e., the RAinduced VE differentiation was restored at late time (14 d) of RA treatment (data not shown).
We also analyzed the mRNA levels of collagen type IV␣1, laminin B1 and AFP in WT and mutant F9 cells (Fig. 4 B) . After 10 d of aggregate culture in the presence of 50 nM tRA, the three markers were similarly induced in WT, RXR␣ 
cells. In RAR␥
Ϫ/Ϫ cells, the induction of laminin B1 was similar to that of WT cells, whereas the induction of collagen IV␣1 was slightly reduced (twofold lower than in WT cells). In contrast, the induction of AFP, a specific marker of VE differentiation, was hardly detectable in RAR␥ Ϫ/Ϫ cells after 10 d of RA treatment (Fig. 4 B) Taneja et al., 1996) and all three RXRs (panRXR, BMS188, 649 [BMS649] ; also known as SR11237; Lehmann et al., 1992; see Roy et al., 1995) (Table I). In WT cells, VE differentiation was triggered by 100 nM of the RAR␥ agonist as effectively as by 50 nM tRA, and it was synergistically induced by a combination of 10 nM RAR␥ and 1 M panRXR agonists (Table I ). In contrast, VE differentiation of RAR␣ Ϫ/Ϫ cells was triggered by 10 nM RAR␥ agonist as efficiently as by 50 nM tRA, and it was even synergistically induced by 1 nM of the RAR␥ agonist in combination with 1 M panRXR agonist, indicating that RAR␣ partially hinders the RAR␥ function in WT cells. The RAR␥ agonist alone, or together with the panRXR agonist, was more efficient in RXR␣ Ϫ/Ϫ and RXR␣
Ϫ/Ϫ
/RAR␣ Ϫ/Ϫ cells than in WT cells, but weaker than in RAR␣
Ϫ/Ϫ cells, demonstrating that RXR␣ prevents an efficient synergism between RXR(␤ϩ␥) and RAR␥ (Table I; see Table IV ). As expected, no VE differentiation was observed in RAR␥ Ϫ/Ϫ and RXR␣ Ϫ/Ϫ / RAR␥ Ϫ/Ϫ cells treated with the RAR␥/panRXR agonist combination.
The RAR␣ agonist, BMS753, on its own did not trigger VE differentiation of WT and RXR␣ Ϫ/Ϫ cells, whereas the combination of 100 nM RAR␣ and 1 M panRXR agonists was much less efficient than the RAR␥/panRXR agonist combination. As expected, no VE differentiation was 
WT and mutant F9 cell aggregates were treated for 10 d with the indicated retinoids, and their differentiation was scored according to the proportion of outer layer of cells displaying VE morphology. ϩϩϩ, more than 80%; ϩϩ, 50-80%; ϩ, 10-50%; Ϯ, not more than 10%; (Ϫ), no visible effect; ND, not determined. *After 14 d of treatment. ‡ After 12 or 18 d of treatment, Ͻ10% of the aggregates exhibited a spotty VE morphology only. The RAR␣, RAR␤, RAR␥, and panRXR agonists were BMS753, BMS453, BMS961, and BMS649, respectively (see text). § After 12 or 18 d of treatment. Note that this visual scoring correlated well with the determination of the relative level of induction of ␣-fetoprotein RNA using semi-quantitative RT-PCR (Fig. 4 B) . 
seen in RAR␣
/RAR␥
Ϫ/Ϫ cells, as in the case of the RAR␣/pan-RXR agonist combination (Table I) . Thus, RAR␥ strongly prevents RAR␣ and RAR␤ to synergize with RXR␣, and mutation of RAR␥ artefactually generates functional redundancy between RARs for VE differentiation of F9 cells (see Table IV ). WT and mutant F9 cells were treated for 6 d in monolayer culture with the indicated retinoids. In each case, the number of cells was expressed in percent relative to the number of cells grown in 0.1% ethanol, which was taken as 100%. ND, not determined. These values correspond to the average of at least three experiments (Ϯ 10%). RAR␣, RAR␤, RAR␥, and panRXR specific agonists were as in Table I .
The 
Ϫ/Ϫ F9 cells was investigated (Fig. 5 A) . After 6 d of 1 M tRA treatment, the inhibition of growth as determined by cell counting, was lower for RXR␣ Ϫ/Ϫ than for WT cells (58 and 79% inhibition relative to untreated control cells, respectively) . The antiproliferative effect of tRA was decreased to the same extent for RXR␣ (Fig. 5 B) (Fig. 5 C) Fig. 5 C, compare b, d, and f) . Interestingly, the cell cycle profile of RXR␣
Ϫ/Ϫ
/RAR␥
Ϫ/Ϫ cells was not significantly affected by tRA treatment, and was almost identical to that of untreated WT cells (Fig. 5 C, compare h with g and a).
To further dissect the roles of RARs and RXRs in the control of proliferation, WT and mutant F9 cells were treated for 6 d with tRA or receptor-selective retinoids, and cell numbers were counted (Table II) . In WT cells, 100 nM RAR␥ agonist efficiently reduced the proliferation, and 10 nM of the same agonist, which had no effect on its own, synergized with 1 M panRXR agonist. The effect of these retinoids on proliferation was reduced, while not abolished, in RXR␣ Ϫ/Ϫ and RXR␣
Ϫ/Ϫ
/RAR␣ Ϫ/Ϫ cells, indicating that RXR␣ can be partially replaced by RXR(␤ϩ␥) for synergizing with RAR␥ (see Table IV ). Interestingly, the RAR␥/panRXR agonist combination was more efficient in RAR␣ Ϫ/Ϫ cells than in WT cells, revealing that RAR␣ partially hinders the antiproliferative effect of RAR␥ in WT cells (Table II; see Table IV ). As expected, this combination did not inhibit the proliferation of RAR␥ Ϫ/Ϫ and RXR␣
/RAR␥ Ϫ/Ϫ cells. The combination of 100 nM RAR␣ and 1 M panRXR agonists, which reduced the proliferation of WT cells less efficiently than the RAR␥/panRXR agonist combination, was more efficient in RAR␥ Ϫ/Ϫ cells than in WT cells (Table II) , indicating that RAR␥ partially hinders the antiproliferative effect of RAR␣ in WT cells (see Table IV ). The RAR␣/panRXR agonist combination had no effect on the proliferation of RXR␣ Ϫ/Ϫ cells, showing that RAR␣ can only synergize with RXR␣ to inhibit proliferation (see Table IV) .
Surprisingly, a treatment with 10 and 100 nM RAR␣ agonist increased the number of RXR␣ 
/RAR␥
Ϫ/Ϫ cells, and that this effect was enhanced by addition of 1 M panRXR agonist. Thus, the presence of RAR␥ not only hinders the antiproliferative effect of the RXR␣/RAR␤ pair, but also the proliferation-promoting effects of the combinations of RXR(␤ϩ␥) with RAR␤, showing again that knockouts generate artifactual effects not observed under WT conditions, as already seen above in the case of F9 cell differentiation (see Table IV ).
Function of RXRs and RARs for the Retinoid-induced Apoptotic Response of F9 Cells
Since retinoids can induce apoptosis, which also contributes to the decrease in cell number in retinoid-treated F9 cells (Atencia et al., 1994) , we determined the extent of the tRA-induced apoptotic response of WT and mutant F9 cells by FACS ® analysis. Sub-2N-size, DNA-containing particles corresponding to "apoptotic bodies" appeared in WT cells after 5 d of tRA treatment, whereas they were not detected in tRA-treated RXR␣ Ϫ/Ϫ (see also (Fig. 6, a, b , e, and f; Table III ). In contrast, tRA-induced apoptosis was reduced in RAR␥ Ϫ/Ϫ cells, rarely seen in RXR␣ Ϫ/Ϫ and RXR␣ (Fig. 6, c, d , and g-l; Table III ). Note that a background level of apoptosis occurred at high cell density even in the absence of tRA, as previously mentioned .
To further investigate the role played by the different RAR and RXR isotypes in apoptosis, WT and mutant F9 cells were treated for 6 d with receptor-selective retinoids, and stained with Hoechst dye (Table III) . In WT cells, 100 nM RAR␥ agonist triggered apoptosis, and the addition of 1 M panRXR agonist resulted in a synergistic effect. The effect of these retinoids was markedly reduced in RXR␣ Ϫ/Ϫ and RXR␣
Ϫ/Ϫ
/RAR␣
Ϫ/Ϫ cells, indicating that RXR␣ can only poorly be replaced by RXR(␤ϩ␥) for this response (Table IV) . In contrast, the RAR␥/panRXR agonist combination was more efficient in RAR␣ Ϫ/Ϫ cells than in WT cells, indicating that RAR␣ partially prevents the apoptotic response mediated by RAR␥ in WT cells (Table IV) . As expected, this combination had no effect on the apoptosis of RAR␥ Ϫ/Ϫ and RXR␣ (Table III) . 100 nM Am80, which acts as panRAR agonist at this concentration (Hashimoto et al., 1990 ), was as efficient as 100 nM RAR␥ agonist for WT, RXR␣ (Table III) . Thus, RAR␥ fully prevents the weak apoptotic response that can be mediated by the RXR␣/RAR␣ and RXR␣/ RAR␤ pairs, and mutation of RAR␥ artifactually generates some functional redundancy (Table IV) .
Discussion
In vitro studies using either cell-free systems or cultured cells cotransfected with vectors overexpressing the various retinoid receptors and cognate recombinant reporter genes, have suggested that RXR/RAR heterodimers could be the functional units transducing the retinoid signal in vivo. These studies have also indicated that the various RXR/RAR heterodimers, resulting from the combination of either one of three RXRs (␣, ␤, or ␥) with either one of the three RARs (␣, ␤, or ␥), could be differentially involved in the numerous physiological events that are controlled by retinoids in vivo (Chambon, 1994 (Chambon, , 1996 . The results of RAR and RXR gene knockout studies in the mouse have supported these suggestions, but their interpretation remains equivocal, in particular because cell- 
